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Summary 
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common childhood behavioural 
disorder – systematic reviews indicate that the community prevalence of ADHD globally is 
between 2% to 7%, with an average of around 5%. In addition, a further 5% of children have 
significant difficulties with over-activity, inattention and impulsivity that are just sub-threshold 
to meet full diagnostic criteria for ADHD. Estimates of the administrative (clinically diagnosed 
and/or recorded) prevalence vary worldwide and although increasing over time, ADHD is still 
relatively under-recognised and under-diagnosed in most countries, particularly in girls and 
older children. ADHD often persists into adulthood and is a risk factor for other mental health 
disorders and negative outcomes including educational under-achievement, difficulties with 
employment and relationships, and criminality. The timely recognition and treatment of 
children with ADHD-type difficulties provides an opportunity to improve their long-term 
outcomes. This review includes a systematic review of the community and administrative 
prevalence of ADHD in children and adolescents; an overview of the barriers to accessing care 
for ADHD; a description of costs associated with ADHD; and a broad discussion of evidence-
based pathways for the delivery of clinical care, including a focus on key issues for two specific 
age groups - pre-school children and adolescents requiring transition of care from child to adult 
services.  
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Background 
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common childhood behavioural 
disorder, estimated to affect around 3-5% of children.1 The diagnosis of ADHD is based on 
pervasive, developmentally excessive and impairing levels of over-activity, inattention and 
impulsivity. At least a further 5% of children have significant difficulties with these behaviours 
that are just sub-threshold to meet full diagnostic criteria. ADHD often persists into adulthood 
and is a risk factor for a wide range of other mental health problems including defiant, 
disruptive, and antisocial behaviours, emotional problems, self-harm and substance misuse as 
well as broader negative outcomes such as educational under-achievement and exclusion from 
school, difficulties with employment and relationships, and criminality.2-4 For health, education 
and social care services, the timely and appropriate recognition and treatment of children with 
ADHD-type difficulties provides an opportunity to enhance their long-term outcomes. This 
review comprises a systematic review of the community and administrative prevalence of 
ADHD in children and adolescents; an overview of the barriers to accessing care; a description 
of costs associated with ADHD; and a discussion of evidence-based pathways and the delivery 
of clinical care, with consideration of specific issues relating to two age groups (pre-school 
children and adolescents requiring transition into adult services). Although ADHD treatments 
are not discussed in detail, key approaches to intervention are outlined as they apply to care 
pathways. 
 
Prevalence of ADHD 
 
Community prevalence 
 
Community prevalence describes the number of people with ADHD in a representative 
population sample, according to predefined criteria. A series of searches (see Panel) identified 
seven systematic review articles reporting on the community prevalence of ADHD.  
 
The first review (Polanczyk) estimated the global prevalence of ADHD as 5.29%.5 Based on 
DSM-IV criteria and using symptoms from parent ratings, teacher ratings or best estimate 
diagnostic procedures, Willcutt estimated a prevalence of 5.9%-7.1% amongst children and 
adolescents.6 In contrast, Erskine et al’s meta-analysis adopted a more conservative approach 
by applying a greater weight to studies where information was required from more than one 
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informant and also included a higher proportion of 12-18 years olds than the Polanczyk 
review.7 They estimated the global prevalence of ADHD amongst 5-19 year olds as 2.2%, with 
a peak prevalence at the age of 9 years. Polanczyk et al. updated their previous review, 
including 154 studies using either DSM or ICD diagnostic criteria in people aged 18 or under, 
and concluded that the world-wide community prevalence of ADHD is approximately 5%.8 
Variation in estimated prevalence was best explained by methodological differences between 
studies so that when similar methodologies are adopted there was no obvious variation between 
different geographical locations. Neither were there differences by study year, suggesting that 
the community prevalence of ADHD has remained stable over the last three decades. Using 
prevalence data from their previous review (the Global Burden of Disease Study 2010),7 
Erskine et al conducted a further systematic review to estimate the disability adjusted life years 
(DALYs) related to ADHD. ADHD was reported to contribute 491,500 DALYs, making it the 
98th highest cause for global burden. The number of DALYs for ADHD peaked at ages 10-14 
years and was higher for males. As part of a broader meta-analysis of the worldwide prevalence 
of mental disorders in children and adolescents, Polanczyk et al. estimated the prevalence of 
ADHD in 6-18 year olds as 3.4% (95% CI 2.6 to 4.5) with heterogeneity in methods between 
studies cited as a reason for different prevalence estimates.10 The final review, by Thomas et 
al., included studies in any language which used DSM-III, DSM-III-R or DSM-IV criteria.11 
The overall prevalence was reported as 7.2% (95% CI 6.7 to 7.8) with studies from Europe 
reporting lower prevalence estimates than those from North America and few studies using 
random population sampling. Collectively, these systematic reviews suggest that the reported 
range in the community prevalence of ADHD (between 2.2% and 7.2%) reflects variation in 
study methodology. 
 
Administrative (clinically recorded) prevalence 
 
This reflects the number of people with clinically diagnosed and/or recorded ADHD as a 
proportion of the whole population i.e. the prevalence of diagnosis made in practice.12 These 
figures, when considered alongside other factors such as community prevalence and the 
availability and use of services, can inform the planning of service provision to address any 
significant discrepancies that might emerge. However, many studies have estimated 
administrative prevalence using only prescription data. These require careful and cautious 
interpretation as a number of factors can influence both the prescription and uptake of 
medication treatments for ADHD, after a clinical diagnosis has been made. The balance 
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between the use of pharmacological and non-pharmacological treatment options for ADHD 
varies greatly both between and within different countries. In general, however, studies that 
only report prescription data are likely to reflect an under-estimate of the true administrative 
prevalence. A series of searches (see Panel) identified 55 papers reporting on the administrative 
prevalence of ADHD.  
 
In the US, whilst it is difficult to make direct comparisons between studies (Table 1)13-37 
because of differences in how administrative prevalence was defined and estimated, the 
administrative prevalence based on prescriptions ranged from 0.6% (in under 18 year-olds in 
1987)32 to 10% (in 7-11 year-olds in 1995-1996).31 The latter figure is higher than other studies 
from that time and may reflect a regional variation. The administrative prevalence based on 
diagnosis ranged from 0.93% (in 2-5 year-olds in 2002)20 to 11.0% (in 4-17 year olds in 2003 
to 2011).18 The pattern of an increase in the prevalence of ADHD over time was reported across 
studies with a peak involving the 10-14 year age group.  
Table 1 about here 
 
Table 2 summarises studies conducted in the UK.38-44 None of these studies estimated the 
administrative prevalence of ADHD based only on diagnosis. Based on prescriptions, the 
prevalence ranged from 0.003% (in under 19 year-olds in 1992)43 to 0.92% (in 6-12 year-olds 
in 2008).40 The administrative prevalence based on prescriptions with/without diagnosis ranged 
from 0.19% (in 6-17 year-olds in 1998)39 to 0.76% (in 5-15 year-olds in 2011-2012).38 Using 
the Health Improvement Network (THIN) primary care database, the prevalence of ADHD 
between 2003 to 2008 was estimated as 0.73% in 6-12 year-olds, 0.57% in 13-17 year-olds and 
0.06% in 18-24 year-olds.40 This trend for decreasing prescriptions has been noted after the age 
of 15 years.41 Although the administrative prevalence of ADHD has increased over time, there 
is some suggestion that this has now levelled off, for example a UK study using the Clinical 
Practice Research Datalink (CPRD) suggested that the prevalence of diagnosed ADHD has 
decreased since 2007.39 
Table 2 about here 
 
Table 3 summarises studies conducted globally outside the US or UK.45-67 In all countries 
except Israel the administrative prevalence estimates were lower than in the US. The 
administrative prevalence based on prescriptions ranged from 0.06 (in 5-17 year olds in 2010-
2011)47 to 2.5% (in under 18 year-olds in 2004).65 The administrative prevalence based on 
5 
 
diagnosis ranged from 0.06% (under 18 year-olds in 1996)62 to 12.6% (in 6-13 year-olds in 
2003 to 2009).56 Two studies using Israeli health insurance data reported relatively high 
prevalence estimates in Kibbutzim areas - 5.99% based on prescriptions;66 12.6% based on 
diagnosis.56 It is possible that these high estimates reflect a selected population of people with 
access to health insurance that are not reflective of the wider population, especially since the 
reported prevalence of ADHD based on prescriptions was 0.20% in Arab areas.66  
Table 3 about here 
 
Differences by sex 
 
Although ADHD is more common in males than females with a ratio of 2-3:1 reported in 
community prevalence studies, the sex ratio is consistently greater in administrative prevalence 
studies. This suggests a relative under-recognition of ADHD in females.6,7 For example, a UK 
study conducted using THIN data (2010-2012) concluded that males are five times more likely 
to be diagnosed with ADHD than females and a study based on diagnosis and prescription data 
from Germany estimated a 3-4 times greater administrative prevalence in males than 
females.38,61 A study from the Netherlands estimated that 3-8 times more boys than girls 
received prescriptions for ADHD and suggested that the administrative prevalence of ADHD 
has been rising faster in boys.68 In the UK, a study using prescriptions data from the CPRD 
estimated that, amongst under 19 year-olds, the male to female ratio of the prevalence of 
ADHD increased over time between 1992 and 2001.43 In contrast, other studies from the US, 
Switzerland, the Netherlands and Sweden have suggested a more rapid increase in females than 
males.24,62,58,69 Similarly, a study of 6-17 year olds using CPRD diagnoses and prescriptions 
data showed that the male to female ratio has reduced over time, ranging from 8.4 in 1999 to 
5.8 in 2009.39 In another study, using THIN data, the male to female ratio also reduced from 
6.6 in 2003 to 5.5 in 2008 in people aged 6-12 years and from 9.8 (2003) to 6.3 (2008) in people 
aged 13-17 years.40 Collectively, these studies suggest that the initial increase in prescribing 
prevalence was mainly in males but that, in more recent years, prescribing has also increased 
for females. 
 
Differences by socio-economic deprivation 
  
A few studies have stratified estimates of community prevalence of ADHD according to socio-
economic deprivation.6 These studies indicate that individuals from families defined as more 
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deprived were between 1.5-4 times more likely to have ADHD than individuals from less 
deprived families. In contrast, there are mixed findings, particularly from the US, on the 
association between the administrative prevalence of ADHD and deprivation. For example, a 
nationwide survey reported that areas with greater levels of deprivation have a higher 
administrative prevalence of ADHD (based on parent report of clinical diagnosis) compared to 
areas with lower levels of deprivation.70 Similarly, a study of primary school children found 
that children from the lowest income quintile had the greatest probability of being reported to 
have a clinical diagnosis of ADHD compared to the middle income quintile.71 However, some 
US-based studies have suggested a greater prevalence of childhood ADHD amongst families 
with a higher income.72,73 Although this association was not explained by the availability of 
health insurance,73 it is less clear how the administrative prevalence of ADHD varies according 
to private and public health insurance status. For example, a household survey with pharmacy 
data on 2.8 million children and adolescents found a drug-treated prevalence of ADHD of 1.3% 
amongst those without insurance, 3.4% with private insurance and 4.3% with public 
insurance.22 Studies from countries where access to healthcare is more universally available 
have generally confirmed an association between the administrative prevalence of ADHD and 
deprivation.74-76  
 
Barriers to care 
 
As noted above, the community prevalence of ADHD globally is estimated to be between 2-
7%, with an average of around 5%, and a suggestion that most of the variation reflects 
methodological differences across studies rather than a true variation between different regions. 
Estimates of the administrative prevalence also vary worldwide, with the highest estimates 
coming from the US and Israel. Although the community prevalence of ADHD has remained 
stable over time, its administrative prevalence has been increasing. This is likely to reflect 
better identification and awareness of the condition and improved access to treatment in 
countries where under-diagnosis has been an issue but may, in some instances, reflect over-
diagnosis. These overall figures also mask regional variations within countries. There are 
particular concerns about rates of prescribing in some parts of the US as these far exceed what 
would be expected from epidemiological data.77,78 This may reflect sub-threshold difficulties 
being diagnosed and treated as ADHD. Data from other countries mainly indicate that ADHD 
is still relatively under-recognised and under-diagnosed, particularly in girls and older children. 
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For example, two reviews of ADHD care across Scotland reported low rates of diagnosis with 
minimal increases over time (0.6% of school-aged children in 2007 and 0.7% in 2012) and ten-
fold variations between regions.79,80 Patterns of prescribing of ADHD medications also show 
significant regional variations across the US,21 Scotland81 and Australia82 amongst others. 
 
In the UK, national data from 2004 suggested that less than half of children with ADHD have 
been diagnosed and receive treatment.83 However, this picture of under-diagnosis co-exists 
alongside some societal and media concerns about increases in methylphenidate prescribing in 
the UK.84 A closer look at prescribing trends in the UK suggests that whilst prescription rates 
have increased considerably over the past 20 years, the actual rates of prescribing remain much 
lower than one would predict from the epidemiological data.40,41 Furthermore, the rate of 
increase in prescribing has slowed considerably in recent years.39 Under-recognition of ADHD 
in many countries may reflect particular barriers to care for these children and young people. 
A systematic review of the international literature highlighted that barriers operate at multiple 
levels, including identification of need and entry into care.85 Socio-demographic factors 
identified as barriers to accessing care included female gender, older age, non-white ethnicity, 
rural residence and lower family socio-economic status. The importance of enhancing 
knowledge about ADHD amongst parents, teachers and primary care clinicians and the need 
to reduce ADHD-related stigma were noted. The review recommended that interventions that 
enhance the knowledge of and communication between these key adults may improve access 
to care. Streamlining care pathways (e.g. liaison and consultation models between primary 
healthcare professionals, specialist education professionals and specialist children’s health 
services) may also help to overcome barriers to access.85 
 
Costs of ADHD 
 
ADHD has a huge impact on the lives of affected children and their families. As well as direct 
use of health, specialist education, social care, and criminal justice services, the wider costs to 
society also reflect impacts on parental employment and mental health, family-borne expenses, 
and crime and offending.  
 
A review of the US literature on the cost of illness related to ADHD has emphasised the 
considerable and persistent costs incurred at both the individual and societal level.86 In the US, 
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the total annual costs have been estimated at between $143billion-$266billion. The majority of 
these costs were attributable to family members of people with ADHD or to adults with ADHD; 
the economic impact being approximately three times greater for affected adults compared to 
children and adolescents. The cost burden mainly related to healthcare and educational services 
for children and loss of income and productivity for adults. 
 
In the UK, the impact on educational services has been confirmed in longitudinal studies. Data 
from the nationally representative British Child and Adolescent Mental Health survey were 
assessed for resource use and estimated costings over a three year follow-up period.87 Children 
with hyperkinetic disorder (using ICD-10) incurred greater costs than children with emotional 
disorders, mainly relating to the use of frontline and special educational services. In England 
and Wales, in 2006, basic NHS costs for ADHD (excluding medication) were estimated at £23 
million for initial specialist assessment and £14 million annually for follow-up care.88 For 2012, 
drug costs for ADHD in England were estimated to exceed £78 million.89 A study conducted 
using the CPRD estimated that the mean annual total healthcare costs for people with ADHD 
were higher than for people without (£1,327 vs. £328 per year, in the first year of the study).39 
Another UK study estimated resource use costs in relation to a sample of 12-18 year olds who 
were referred to specialist healthcare services and received a clinical diagnosis of ADHD five 
years earlier.90 Based on 2010 prices, the estimated annual total costs to the NHS, social care, 
and education services were estimated at £670 million. The majority (76%) of the mental 
health-related costs fell to the education sector. 
 
Evidence is also emerging from longitudinal studies about the long-term cost impacts of 
childhood attention and hyperactivity problems, even if sub-threshold to meet full ADHD 
diagnostic criteria. Over an 11-22 year follow-up period, when compared with controls, a 
community sample of pre-school children at risk of ADHD had 17.6 times higher average costs 
per annum across most domains (apart from non-mental health costs).91 Attention and 
hyperactivity problems at the age of 10 are associated with lower levels of employment and 
earnings at age 30.92 Another community-based 20 year follow-up study highlighted the 
importance of comorbid conduct problems in childhood in terms of incurring recent costs 
related to receipt of state benefits and use of general health and social care services.93 Delays 
in receiving a clinical diagnosis of ADHD also result in greater long-term costs -  individuals 
with ADHD who were not diagnosed until adulthood cost 13,608 euros more per year than 
their same-sex sibling.94 
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Evidence-based Care Pathways  
 
Diagnostic controversies and difficulties 
 
Even in countries where ADHD is now more generally accepted, ADHD remains a 
controversial diagnosis in society and also amongst some professionals who work with children 
e.g. clinicians, teachers, and social care professionals. This is in contrast to other 
neurodevelopmental conditions such as autism where the diagnosis is often less contentious. 
Whilst these concerns are often lumped together they actually reflect a range of quite distinct 
issues. These include the lack of any specific objective tests to diagnose ADHD, the fact that 
ADHD symptoms reflect the extreme end of a spectrum that spans the entire population, the 
perception of a somewhat arbitrary cut-off for symptoms and impairment that itself requires a 
degree of individual judgement, the broadening of the diagnostic criteria over time, variation 
amongst clinicians and services in rates of diagnosis and the use of medication (in particular, 
stimulant medications) for ADHD. The absence of a diagnostic test for ADHD does not, 
however, invalidate the diagnosis. This issue applies to all psychiatric disorders and many 
physical conditions such as hypertension.95 Compared to other psychiatric disorders in the 
DSM5 field trials, the assessment of ADHD was one of the most reliable diagnoses with a 
pooled test-retest reliability (intra-class kappa) across sites of 0.61. This was only exceeded by 
major neurocognitive disorder (0.78) and autism (0.69) and was much higher than the figures 
for disorders such as schizophrenia (0.46), bipolar disorder (0.56), major depressive disorder 
(0.28) and generalized anxiety disorder (0.20). Data from routine clinical practice (involving a 
clinical sample of 502 cases) in the UK indicated that, although some ADHD cases are missed 
(false negatives), the only 'false positive' case was one that had become sub-threshold following 
appropriate treatment.96 Based on the evidence outlined above, although there appears to be an 
issue with over-diagnosis in some parts of the US with the risk of misdiagnosis (false positives) 
if clinicians take short-cuts during assessment, the diagnosis of ADHD can be made both 
accurately and reliably if the assessment is conducted carefully using standardised approaches.1 
 
Whilst the recommendations of published ADHD guidelines are on one level very clear and 
consistent,1,97-101 clinicians often complain that guidelines are still somewhat vague, 
particularly in relation to assessment and diagnosis.102 Many clinicians perceive the assessment 
and diagnostic decision-making processes to be inherently complicated as it requires both time 
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and experience to piece together information gathered.102 From an applied health research 
perspective, there is a need to understand whether interventions that assist clinicians in 
optimising the assessment and diagnostic decision-making process also improve the clinical 
outcomes of children and adolescents with ADHD.  
 
Within child psychology and psychiatry there is also an ongoing debate about whether some 
of those cases currently diagnosed as having ADHD would actually be better understood using 
an attachment or trauma paradigm and vice versa.103 However, this is not an either/or debate 
and there are strong theoretical reasons why these disorders may often co-exist. However, it is 
a question that has been relatively neglected by researchers and merits further attention. 
 
Service Organisation  
 
In addition to the variability in administrative prevalence noted above, there are also 
considerable global differences in the way that clinical care for ADHD is organised.104 
Although this partly reflects general differences between healthcare systems (e.g. the balance 
between public and privately funded systems), there are also historical and cultural differences 
in the acceptance of ADHD as a valid disorder and of pharmacological and non-
pharmacological treatments for child and adolescent mental health problems in general and 
ADHD more specifically.  
 
In the UK, diagnosis is normally made by paediatric or child and adolescent psychiatry 
specialists within secondary healthcare, depending on locally agreed care pathways. Although 
these physicians usually work within the context of a multi-disciplinary team, the involvement 
of non-medical professionals in the assessment process varies considerably according to local 
service organisation and structures. Ongoing care and treatment is supervised by secondary 
care with shared care arrangements for medication prescribing, in some places, with primary 
care. In the US, where much healthcare provision is delivered privately, ADHD is generally 
managed by primary care paediatricians or child and adolescent psychiatrists working in 
relative isolation with few cases managed within a multi-disciplinary team. ADHD is now 
generally recognised as a valid and important disorder in some parts of the world including 
North America, northern Europe and several other regions. However, there are still many 
countries including much of Africa, Asia, Central and South America and parts of Southern 
Europe where ADHD is less well accepted, rates of recognition remain low and the scant 
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resources available for treatment tend to be mainly focused on teaching hospital or tertiary 
centres rather than in community settings. Where service access is limited, telehealth service 
delivery models for managing ADHD can be effective and merit further investigation around 
their acceptability and cost-effectiveness.105 
 
Clinical Guidelines and Treatment Recommendations 
 
There are now a broad range of evidence-based guidelines, mainly from North America and 
Europe, addressing both the assessment and management of ADHD.1,97-101 The most notable 
aspect about these guidelines is that, despite the different international traditions and 
perspectives on ADHD noted above and different approaches to their development, they are 
very similar in their recommendations for assessment and many aspects of treatment. They all 
agree that assessment should be relatively structured and comprehensive, including assessment 
of general functioning and comorbid disorders in addition to the core ADHD assessment. 
Although they all recognise the potential importance of both pharmacological and non-
pharmacological treatment approaches for ADHD, the main area of divergence relates to the 
order in which treatments should be offered to those with a new diagnosis. North American 
guidelines generally recommend that medication should be considered as a first-line treatment 
in most cases whereas guidelines from Europe suggest that, whilst medication is appropriate 
as an initial treatment for more severe cases, behavioural management approaches should be 
offered first for less severe cases. These recommendations reflect a more conservative approach 
towards medication in Europe as well as data from the Multimodal Treatment of ADHD (MTA) 
randomised controlled trial (RCT) which suggested that, for symptom reduction, medication 
was superior to behavioural treatment for those with more severe ADHD but that the 
differences were less striking for less severe cases.106  
 
However, it is likely that these decisions will need to be re-assessed on the basis of a series of 
carefully conducted meta-analyses.107,108 These analyses suggest that, when considering 
outcomes from the perspective of a probably blinded informant, behavioural treatments appear 
to improve parenting and conduct problems but are relatively ineffective at reducing ADHD 
symptoms. In contrast to these analyses, even the most conservative approaches to assessing 
the effectiveness of pharmacological treatments for children and adolescents with ADHD 
suggest moderate to large effect sizes with respect to ADHD symptoms in school-age children. 
Although this has been replicated across a number of systematic reviews, a Cochrane review 
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that also reported moderate to high effect sizes for methylphenidate urged caution in its use.109 
This conclusion was based on the authors’ interpretation of the risk of bias in the included 
studies which, in their view, resulted in a very low quality of evidence. This is in direct contrast 
to the conclusions of NICE which rated the evidence to be of moderate to high quality.1 Several 
aspects of the methodology and authors’ interpretation of this Cochrane review have been 
challenged.110-112 These reviews also highlight that whilst ADHD medications are associated 
with a range of non-serious adverse effects there is as yet little evidence for serious adverse 
events. Whilst these data are encouraging, they refer in general to relatively short-term effects 
from highly structured RCTs that are unlikely to accurately reflect usual clinical practice. There 
are, however, encouraging data which support the positive effects of ADHD medications on 
more naturalistic measures of outcome.4,113,114 There remains a poverty of data regarding the 
longer-term benefits and risks associated with drug treatments for ADHD. In part, this reflects 
the inherent difficulties associated with collecting such data, particularly in terms of running 
long-term RCTs of ADHD medications, and with interpreting data from long-term 
observational studies that lack a comparison group. Looked at collectively, the evidence 
suggests that whilst behavioural treatments are likely to benefit many children with ADHD, 
they are less likely to reduce ADHD symptoms. It would therefore seem appropriate, at least 
for school-aged children, to consider medication as a first-line treatment as part of a 
comprehensive treatment package that will often include non-pharmacological interventions.  
 
Implementing guidelines into practice 
 
Relatively little is known about how well ADHD guidelines are implemented into routine 
clinical practice. However, in Scotland, there have been two national reviews of adherence to 
the SIGN guidelines for ADHD. The first review highlighted that, whilst adherence to 
guidelines was generally fairly good, there were significant variations in practice across the 
country, particularly with respect to the administrative prevalence that ranged between 0.2-
1.0%.79 The second review noted improvements in service developments and recommended 
further work particularly around recognition, capacity building, outcome measurement, 
partnership with other agencies and transition services into adulthood.80 Many published 
guidelines lack the detail and organisational structure required to make them readily 
implementable in day-to-day practice. In an attempt to address this, the European ADHD 
guidelines have been operationalised into a format that describes the steps required at each 
stage of the process.115,116 
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Data from the MTA study suggested that, for children with combined type ADHD, a well-
organised medication package of care resulted in enhanced clinical outcomes at 14 months 
compared to a comprehensive package of behavioural treatment or community care and that 
the combination of the medication and behavioural treatments was similar in most respect to 
medication alone.117 Longer term naturalistic follow-up of these children highlighted continued 
effects for all groups but that the additional benefits seen in the medication groups were not 
sustained over time.118 Whilst some authorities have argued that these findings suggest that 
medications do not work in the long term, an alternative explanation is that the added effect of 
more intensive medication management diminishes once the intensive control of treatment is 
relaxed.119 Supporting this notion, Coghill and Seth have demonstrated continued benefits up 
to ten years after titration using a carefully crafted clinical care pathway that aimed to optimise 
symptom control within a routine clinical setting.120 Unfortunately, such strong outcomes are 
not typical of the literature.121 Recent work assessing UK clinicians' attitudes towards 
implementing medication management strategies in routine practice suggests that although key 
recommendations from guidelines are seen as important and feasible to implement, others 
present considerable implementation challenges in practice.122 Collectively, these findings 
suggest that there needs to be greater use of implementation science approaches to ensure that 
clinicians work towards implementing evidence-based protocols and that these efforts achieve 
the desired clinical outcomes. 
 
Consideration of specific age-groups 
 
Pre-schoolers with ADHD 
 
Although initially considered a disorder of childhood there is now convincing evidence and 
wider acceptance that ADHD is a lifespan disorder with early onset and is associated with 
considerable burden and costs.123 Chorozoglou et al highlighted the long-term costs associated 
with pre-school ADHD; higher costs were consistently predicted by male gender and, for some 
cost codes, conduct problems.91 Identification of ADHD during the pre-school years is often 
complicated by the fact that ADHD symptoms are typical behaviours that are developmentally 
inappropriate for the child’s age.124 Maniadaki et al explored parents’ understanding of child 
behaviour problems and their likelihood of help-seeking.125 Parents whose pre-school child 
displayed very high levels of ADHD behaviours tended to perceive these as normal 
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developmental behaviours and were not planning on seeking professional help. This study 
highlights the challenges of identifying young children at risk of ADHD and encouraging and 
ensuring early access to care.85  
 
From a treatment perspective, research evidence shows that pre-school pharmacological 
treatment for ADHD is associated with lower efficacy and higher levels of side effects than for 
school-aged children126 and longer-term follow-up studies suggest high levels of medication 
discontinuation (25%) in pre-school children.127 Although many parents have a preference for 
individual-based treatment,128 guidelines for pre-school ADHD recommend group-based 
behavioural interventions based on social learning theory for ADHD.1 
 
Within a systematic review examining the efficacy of behavioural interventions for children 
with ADHD,108 results of meta-regression indicated larger effect sizes in trials involving 
younger children for outcomes related to positive parenting, ADHD symptoms and conduct 
problems, (as reported by the most proximal informant). In addition, a sensitivity analysis 
exploring trials with no or low medication use (nearly all involved pre-school children) showed 
higher effect sizes. However, when considering the role of behavioural interventions for 
ADHD, clinicians should be aware that very little is known about the impact of mediators and 
moderators on treatment outcomes. Few treatment moderators have been identified although 
parental ADHD strongly influences treatment outcomes, with parents with higher ADHD 
symptoms having children with poorer outcomes.129 In addition, a study with mothers and 
children with ADHD found that treatment of parental ADHD did not influence the outcome of 
behavioural parent training on child ADHD symptomatology.130 Therefore, given the lack of 
evidence to help clinicians identify for whom behavioural interventions might be most 
effective, it would seem prudent to continue to offer these to all parents of pre-school children 
with ADHD.  
 
Transitions between child and adult services 
 
Regardless of the precise service organisation, which varies between countries, optimum 
transition from child to adult services involves planning, information transfer and joint working 
between teams and should lead to continuity of care during and following the transfer of clinical 
responsibility.131 Successful transition requires resources as well as the acquisition of additional 
skills and knowledge to enable the receiving team to provide continuity of care that meets the 
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young person’s needs, but has been relatively neglected in relation to ADHD.132 In the UK, 
NICE guidelines recommend that, for young people with ADHD who require treatment 
transition to adult mental health services, ongoing review of pharmacological treatment should 
be shared between specialist mental health and primary health care services.1 However, many 
adult mental health practitioners lack experience and training in the management of ADHD, 
and may have negative and sceptical attitudes towards it as a condition that warrants 
intervention.133-135 Similarly, few practitioners in primary/ambulatory care have direct 
experience of child and adolescent psychiatry and may be unfamiliar with the management of 
ADHD without support from specialist services.136 
       
The transition from child to adult mental health services poses particular challenges due to 
differences in training, thresholds and focus between child and adult mental health services, 
leaving a proportion of young people without a clear pathway. Young people often face 
multiple other transitions around the time that children’s healthcare services withdraw, and 
given the nature of ADHD, some young adults with the condition struggle to organise 
themselves to attend appointments and continue treatment. Choices about education, 
occupation and residence during the teenage years can have profound impacts on subsequent 
life chances. Poor transition may result in young people with ongoing needs disengaging from 
services and consequently having worse outcomes.137,138 Studies from European case registers 
suggest that the discontinuation of pharmacological treatment for ADHD among young men is 
associated with an increased risk of serious road traffic accidents and criminal 
convictions;112,139 and with increased accidents, injuries and emergency department attendance 
among children and young people.140 
       
Two multi-methods studies of transition of mental health care have demonstrated that transition 
is often poorly planned, lacks co-ordination and frequently results in discontinuity of care, 
particularly for children with neurodevelopmental disorders.131,141 However, insufficient 
numbers of young people with neurodevelopmental disorders meant that neither study could 
explore transition for young people with ADHD in depth. The limited literature on transition 
in ADHD suggests that policy recommendations are not often translated into practice.142,143 
Findings from the CPRD in the UK have shown a 95% drop in ADHD drug prescriptions for 
young people between the age of 15 and 21 years, with the reduction being most marked 
between the ages of 16 and 17.41 This fall in prescribing is far greater than the expected age-
related decrease in symptoms and suggests the possibility of premature discontinuation of 
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medication among some young people.144 While the management of ADHD is relatively 
common within children’s services, clinicians describe high levels of attrition in attendance at 
school-leaving age, so that relatively few young people with ongoing service needs are referred 
onto adult services. Two of the review authors are currently involved in a multi-method study 
that is gathering prospective data from across the British Isles on the number of young adults 
who require transition, mapping the available services for young adults with ADHD and 
exploring the experience of transition with young people who have ADHD, their parents and 
the practitioners who work with them (http://medicine.exeter.ac.uk/catchus/). 
 
Summary 
 
In this article focusing on children and adolescents with ADHD, we have reviewed and 
highlighted key findings from the international literature relating to the community and 
administrative prevalence of ADHD with an exploration of possible reasons for discrepancies 
between these two sets of figures, barriers and facilitators to care and the cost burden of ADHD. 
We have also discussed a range of aspects that influence the development and implementation 
of evidence-based care pathways for ADHD, with consideration of specific issues relating to 
pre-schoolers and older teenagers who require transition into adult services. 
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Table 1: The administrative prevalence of ADHD reported in studies conducted in the US 
First author Year 
published 
Year 
start 
Year 
end 
Ages Prevalence % (Year, if applicable) and case definition 
Wolraich 2014 Not 
stated 
Not 
stated 
5-13Y 10.1% and 7.4% in two separate states (South Carolina (SC) and Oklahoma (OK)) 
according to medication use. However, this study also estimated community 
prevalence as 8.7% and 10.6% respectively in the same two states. Of those 
medicated, 39.5% (SC) and 28.3% (OK) met the criteria for cases of ADHD. 
MMWR 2015 2011 2014 5-17Y 10% by parents reporting their child has been diagnosed with ADHD in a national 
telephone interview survey. 
Mayne 2016 2009 2014 4-18Y 8.6% by diagnosis recorded in primary care medical record and 9.2% by stimulant 
prescription. 
Fulton 2015 2003 2012 6-13Y 8.6% in 2003, 10.4% in 2007, 11.8% in 2011 by diagnosis reported in the National 
Survey of Children's Health. 
McCabe 2013 2010 2011 18Y Lifetime medical use of stimulants 9.5% in high school students in a national 
questionnaire survey. 
Visser 2014 2003 2011 4-17Y 11.0% had 'ever' received a diagnosis of ADHD in 2011 compared to 8.8% with a 
'current' diagnosis of ADHD in 2011. 4.8% in 2007 and 6.1% in 2011 had 'current' 
medication and diagnosis of ADHD using data from the National Survey of Children's 
Health. 
Tian 2013 2008 2010 4-40Y 1.9% (2008); 2.5% (2010) by diagnosis. 2.4% (2008); 3.5% (2010) by prescription. 
Fontanella 2014 2002 2008 2-5Y 0.93% (2002); 1.31% (2008) based on diagnosis 
McDonald 2013 2008 2008 0-17Y 2.5% (2008) based on prescription 
Zuvekas 2012 2008 2008 0-18Y 2.4% (1996); 3.5% (2008) based on prescriptions 
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First author Year 
published 
Year 
start 
Year 
end 
Ages Prevalence % (Year, if applicable) and case definition 
Centers for 
Disease 
Control 
2010 2003 2007 4-17Y Increase in parent-reported diagnosis from 7.8% to 9.5% during 2003-2007 in results from 
National Survey of Children's Health. 
Castle 2007 2000 2005 0-19Y 4.4% based on prescriptions 
Brinker 2007 2004 2004 1-20Y 3.7% based on prescriptions 
Centers for 
Disease 
Control 
2005 2003 2004 4-17Y In 2003 7.8% had ever had a diagnosis of ADHD. 4.3% ever had a diagnosis of ADHD and 
were taking medication for ADHD. 
Castle 2007 2000 2005 0-19Y 4.4% based on prescriptions 
Brinker 2007 2004 2004 1-20Y 3.7% based on prescriptions 
Centers for 
Disease 
Control 
2005 2003 2004 4-17Y In 2003 7.8% had ever had a diagnosis of ADHD. 4.3% ever had a diagnosis of ADHD and 
were taking medication for ADHD. 
Olfson 2013 2002 2004 13-18Y 2.8% of respondents used a stimulant medicine in the previous year in this national survey. 
Nearly half of the users of stimulants met ADHD criteria in the previous 12 months and an 
additional 13.1% met ADHD criteria in their lifetime. 
Habel 2005 1996 2000 2-18Y 1.86% (1996); 1.93%(2000) based on prescriptions 
Goldstein 2001 1999 1999 5-11Y 1.39% based on prescriptions 
Lin 2005 1990 1997 All 
ages 
3.8% (1997) based on prescription of amphetamines (not methylphenidate) in 10-14Y olds 
LeFever 1999 1995 1996 7-11Y 8% and 10% based on prescriptions in two separate cities. 
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First author Year 
published 
Year 
start 
Year 
end 
Ages Prevalence % (Year, if applicable) and case definition 
Olfson 2002 1987 1996 0-18Y 0.6% (1987); 2.4% (1996) based on prescriptions 
Robison 1999 1990 1995 5-18Y 2.8% (1995) based on prescriptions; 4.5% (1995) based on diagnosis; 3.4% based on 
diagnosis and prescription (1995) 
Zito 2000 1991 1995 2-19Y Increasing prevalence of prescribing over time in all age groups e.g. in one programme 
stimulant prevalence in preschoolers was 1.2% in 1995. 
Wolraich 1996 1993 1994 5-11Y 11.4% in this study had ADHD by DSM-III-R criteria of whom 26% were known to the 
teacher to have had an ADHD diagnosis received stimulant treament. 
Safer 1994 1971 1993 5-18Y 2.1% (1975); 3.6% (1993) in elementary pupils. 0.22% (1983); 0.70% (1993) in senior 
pupils. Based on prescriptions 
Rappley 1995 1992 1992 0-19Y 1.1% based on prescriptions 
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Table 2: The administrative prevalence of ADHD reported in studies conducted in the UK 
First 
author 
Year 
published 
Country Year 
start 
Year 
end 
Ages Prevalence % (Year, if applicable) and case definition 
O'Leary 2014 UK 2010 2012 5-15Y 0.75% (2010-11); 0.76% (2011-12) based on diagnosis and prescription 
Holden 2013 UK 1998 2010 6-17Y 0.19% (1998); 0.55% (2006); 0.51% (2009) based on diagnosis and/or 
prescription 
McCarthy 2012 UK 2003 2008 6-12Y 0.48% (2003); 0.92% (2008) based on prescriptions 
McCarthy 2009 UK 1999 2006 15-21Y 0.09% (1999); 0.51% (2006) based on prescriptions in males 
Wong 2009 UK 2001 2004 15-21Y 0.03% (1999); 0.2% (2006) based on prescriptions 
Hsia 2009 UK 1992 2001 <19Y 0.003% (1992); 0.29% (2001) based on prescriptions 
Jick 2004 UK 1999 1999 5-14Y 0.53% (1999) based on prescriptions in males 
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Table 3: The administrative prevalence of ADHD reported in studies conducted outside the US and UK 
First author Year 
published 
Country Year start Year end Ages Prevalence % (Year, if applicable) and case definition 
Geirs 2014 Iceland 2003 2012 >19Y 0.29% in 2003 and 1.2% in 2012 by prescriptions in a national 
database. 
Pottegard 2014 Denmark 2000 2012 7-12Y 1.2% by prescription in Danish prescription registry. 
Wallach-
Kildemoes 
2015 Denmark 2010 2011 5-17Y 0.06% are prescribed a stimulant medication in national 
electronic health registers. 
Norum 2014 Norway 2004 2011 <19Y Peak of 0.65% aged 0-9 years in Northern region in 2010 and 
low of 0.25% aged 0-9 years in Western region by 
prescriptions. Peak of 2.9% in Northern region in 2011 and low 
of 0.9% aged 10-19 years in Western region by prescriptions in 
national database. 
Boland 2015 Ireland 2002 2011 <15Y 0.38% in 2002 and 0.86% in 2011 by prescription in Irish 
prescription claims register. 
Pottegard 2012 Denmark 1995 2011 All ages Increasing prevalence with calendar year based on 
prescriptions. Peak prevalence 2.4% in 13-17Y old males in 
2011 
Dalsgaard 2014 Denmark 1990 2011 7-20Y 2.08% by prescription in a national database. 
Prosser 2015 Australia 2010 2010 5-17Y 1.24% were diagnosed and medicated in the state of New 
South Wales. 
Okumura 2014 Japan 2002 2010 6-18Y Article in Japanese but personal correspondence with author 
revealed: 0.15% aged 6-12 years and 0.05% aged 13-18 years 
by prescriptions in a nationwide claims database. 
Dalsgaard 2013 Denmark 1990 2010 0-20Y 1.56% based on prescriptions 
Zetterqvist 2013 Sweden 2006 2009 8-14Y 0.66% (2006); 1.26% (2009) based on prescriptions 
Cohen 2013 Israel 2003 2009 6-13Y 12.6% based on diagnosis 
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First author Year 
published 
Country Year start Year end Ages Prevalence % (Year, if applicable) and case definition 
Zoega 2011 Denmark, Finland, 
Iceland, Norway, Sweden 
2007 2007 7-15Y 1.1% based on prescriptions 
Hodgkins 2011 Netherlands 2000 2007 6-17Y 1.1% (2000); 2.1% (2007) based on prescriptions 
Schubert 2010 Germany 2000 2007 <18Y 1.06% (2007) based on prescriptions 
Kraut 2013 Germany 2004 2006 3-17Y 1.5% (2005) based on prescriptions 
Lindemann 2012 Germany 2004 2006 3-17Y 2.5% (2005) based on diagnosis and prescriptions 
Chien 2012 Taiwan 1996 2005 <18Y 0.06% (1996); 1.64% (2005) based on diagnosis 
Gumy 2010 Switzerland 2002 2005 5-14Y 0.74% (2002); 1.02% (2005) based on prescriptions 
Preen 2007 Australia 2004 2004 3-17Y 2.4% based on prescriptions 
Vinker 2006 Israel 1998 2004 0-18Y 0.7% (1998); 2.5% (2004) based on prescriptions 
Fogelman 2003 Israel 1999 2001 0-18Y 5.99% in Kibbutzim; 0.20% in Arab areas based on 
prescriptions 
Miller 2001 Canada 1990 1996 0-19Y 0.19% (1990); 1.1% (1996) based on prescriptions 
 
 
 
 
 
 
